Multiple Sclerosis and Antecedent Infections
Neurol 54:2307-2310, Marrie,R.A.,et al, 2000
Primary Neurosarcoidosis:A Diagnostic and Therapeutic Challenge
The Neurologist 6:126-133, Nikhar,N.K.,et al, 2000
Diagnostic Criteria for Primary Progressive Multiple Sclerosis: A Position Paper
Ann Neurol 47:831-835, Thompson,A.J.,et al, 2000
Heterogeneity ofMultiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination
Ann Neurol 47:707-717, Lucchinetti,C.,et al, 2000
Open-Ring Imaging Sign
Neurol 54:1427-1433, Masdeu,J.C.,et al, 2000
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Neurologic and Developmental Disability After Extremely Preterm Birth
NEJM 343:378-384,429, Wood,N.S. et al, 2000
Functional Outcomes After Gamma Knife Thalamotomy for Essential Tremor and MS-Related Tremor
Neurol 55:443-446, Niranjan,A. et al, 2000
Cerebrospinal Fluid Oligoclonal IgG Bands in Patients With Spinal Arteriovenous Malformation and Structural Central Nervous System Lesions
Arch Neurol 57:553-557, Cohen,O.,et al, 2000
Poliomyelitic-Like Illness in Central European Encephalitis
Neurol 55:299-302, Schellinger,P.D. et al, 2000
Optic Neuritis in Multiple Sclerosis: An Update
The Neurologist 6:205-213, Chan,J.W., 2000
Disability in Young People and Adults One Year after Head Injury: Prospective Cohort Study
BMJ 320:1631-1635, Thornhill,S. et al, 2000
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000
Psychological Stress and the Subsequent Appearance of New Brain MRI Lesions in MS
Neurol 55:55-61, Mohr,D.C. et al, 2000
Acute Aphasia in Multiple Sclerosis
Arch Neurol 57:1207-1209, Devere,T.R. et al, 2000
Health-Related Quality of Life in Neurology
Arch Neurol 57:1224-1227, Meyers,A.R. et al, 2000
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Cerebral Infarctin in the Term Newborn: Clinical Presentation and Long-Term Outcome
J Pediatr 137:351-355, Sreenan,C. et al, 2000
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis
NEJM 343:898-904, Jacobs,L.D. et al, 2000
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Homocysteine and Neurologic Disease
Arch Neurol 57:1422-1428, Diaz-Arrastia,R., 2000
Progressive Forms of MS:Classification Streamlined or Consensus Overturned?
Lancet 355:162-163, Weinshenker,B.G., 2000
Effect of Interferon B-1b in MS, Assessment of Annual Accumulation of PD/T2 Activity on MRI
Neurol 54:200-206, Zhao,G.J.,et al, 2000
A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor
NEJM 342:461-468,505, Schuurman,P.R.,et al, 2000
Total Brain N-Acetylaspartate, A New Measure of Disease Load in MS
Neurol 54:15-19, Gonen,O.,et al, 2000
De Novo Mutation in the Notch3 Gene Causing CADASIL
Ann Neurol 47:388-391, Joutel,A.,et al, 2000
Musculoskeletal and Neurologic Outcomes in Patients with Previously Treated Lyme Disease
Ann Int Med 131:919-926, Shadick,N.A.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
An Algorithm for ALS Diagnosis and Management
Neurol 53:S58-S62, Swash,M., 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Isolated Cranial Nerve Palsies Due to Brainstem Lesions
Muscle & Nerve 22:1168-1176, Thomke,F., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Suppression of Pendular Nystagmus by Smoking Cannabis in a Patient with Multiple Sclerosis
Neurol 53:2209-2210, Schon,F.,et al, 1999
Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999
Chronic Thalamic Stimulation for the Tremor of Multiple Sclerosis
Neurol 53:625-628, Montgomery,E.B.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Chlamydia Pneumoniae Infection of the Central Nervous System in Multiple Sclerosis
Ann Neurol 46:6-14,4, Sriram,S.,et al, 1999
A Longitudinal Study of Brain Atrophy in Relapsing Multiple Sclerosis
Neurol 53:139-148, Simon,J.H.,et al, 1999
Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999
Association of MS with Thyroid Disorders
Neurol 53:883-885, Karni,A.&Abramsky,O., 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999
Olfactory Dysfunction in Multiple Sclerosis:Relation to Longitudinal Changes in Plaque Numbers in Central Olfactory Structures
Neurol 53:880-882, Doty,R.L.,et al, 1999
Isolated Trochlear Nerve Palsy in Patients with Multiple Sclerosis
Neurol 53:877-879, Jacobson,D.M.,et al, 1999